Chemically, it is similar to the controlled substance amphetamine
VIVITA HNG LUN LUN LUN MI *Lu : Sn phm khng phi l thuc v khng th dng thay th thuc tr bnh
Nucleic Acids 22 , 114123 (2020)
Current Challenges in the Development of Platelet-Rich Plasma-Based Therapies
[5] [2] Patients starting GLP-1 therapy should be aware of: Potential mood changes during the adjustment period, particularly if experiencing significant gastrointestinal side effects The importance of continuing existing mental health treatments unless advised otherwise by their healthcare team Realistic expectations regarding weight loss and metabolic improvements, as unrealistic goals can lead to disappointment Healthcare professionals prescribing GLP-1 agonists should: Screen for depression and anxiety at baseline and during follow-up appointments Monitor for mood changes , particularly in patients with pre-existing mental health conditions Ensure coordinated care between diabetes/obesity services and mental health teams when appropriate It is essential to recognise that GLP-1 agonists are not a substitute for evidence-based depression treatments, including psychological therapies and antidepressant medications when indicated
Lupus and Medication Safety Considerations Systemic lupus erythematosus (SLE) , commonly known as lupus, is a chronic autoimmune condition where the immune system mistakenly attacks healthy tissues throughout the body
